GLP-1 medicines have also produced meaningful benefits in individuals living with obesity who are unable to achieve sufficient weight loss through lifestyle changes and who are not eligible for bariatric surgery. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.